<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36271076</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro.</ArticleTitle><Pagination><StartPage>6286</StartPage><MedlinePgn>6286</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6286</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-33332-7</ELocationID><Abstract><AbstractText>A GGGGCC<sub>24+</sub> hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), fatal neurodegenerative diseases with no cure or approved treatments that substantially slow disease progression or extend survival. Mechanistic underpinnings of neuronal death include C9ORF72 haploinsufficiency, sequestration of RNA-binding proteins in the nucleus, and production of dipeptide repeat proteins. Here, we used an adeno-associated viral vector system to deliver CRISPR/Cas9 gene-editing machineries to effectuate the removal of the HRE from the C9ORF72 genomic locus. We demonstrate successful excision of the HRE in primary cortical neurons and brains of three mouse models containing the expansion (500-600 repeats) as well as in patient-derived iPSC motor neurons and brain organoids (450 repeats). This resulted in a reduction of RNA foci, poly-dipeptides and haploinsufficiency, major hallmarks of C9-ALS/FTD, making this a promising therapeutic approach to these diseases.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meijboom</LastName><ForeName>Katharina E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0003-0151-2983</Identifier><AffiliationInfo><Affiliation>Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdallah</LastName><ForeName>Abbas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fordham</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0003-0059-2248</Identifier><AffiliationInfo><Affiliation>Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagase</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Tom&#xe1;s</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8724-5427</Identifier><AffiliationInfo><Affiliation>RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7552-099X</Identifier><AffiliationInfo><Affiliation>RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania F</ForeName><Initials>TF</Initials><Identifier Source="ORCID">0000-0002-7335-2627</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Gopinath</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esanov</LastName><ForeName>Rustam</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade</LastName><ForeName>Nadja S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rybin</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-8578-0891</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramic</LastName><ForeName>Melina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Zachary D</ForeName><Initials>ZD</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences. Mayo Clinic, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edraki</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackwood</LastName><ForeName>Meghan T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahriman</LastName><ForeName>Aydan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henninger</LastName><ForeName>Nils</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kocher</LastName><ForeName>Jean-Pierre A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-0260-6773</Identifier><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences. Mayo Clinic, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodsky</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0001-7703-4872</Identifier><AffiliationInfo><Affiliation>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fen-Biao</ForeName><Initials>FB</Initials><Identifier Source="ORCID">0000-0001-8873-5404</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sontheimer</LastName><ForeName>Erik J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0002-0881-0310</Identifier><AffiliationInfo><Affiliation>RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0001-6062-1528</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeier</LastName><ForeName>Zane</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-0623-8610</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, 33136, USA. zzeier@med.miami.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3589-8749</Identifier><AffiliationInfo><Affiliation>Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA. Christian.mueller4@sanofi.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS111990</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS057553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS101986</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS104022</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>C.M., A.A., and UMASS Medical School are inventors on the patent (number US 2020/035471, still pending) for the gRNA sequences in this work and may be entitled to royalty payments in the future. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>21</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36271076</ArticleId><ArticleId IdType="pmc">PMC9587249</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-33332-7</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-33332-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 2009;4:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Cruts M, Van Broeckhoven C. Relationship between C9orf72 repeat size and clinical phenotype. Curr. Opin. Genet. Dev. 2017;44:117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">28319737</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, et al. C9orf72 intermediate expansions of 24&#x2013;30 repeats are associated with ALS. Acta Neuropathol. Commun. 2019;7:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6637621</ArticleId><ArticleId IdType="pubmed">31315673</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney E, et al. Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile. JAMA Neurol. 2014;71:331&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">24445580</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowicka, N., Juranek, J., Juranek, J. K. &amp; Wojtkiewicz, J. Risk factors and emerging therapies in amyotrophic lateral sclerosis. Int. J. Mol. Sci.20, 2616 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6600314</ArticleId><ArticleId IdType="pubmed">31141951</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick J, Ferguson SM. C9orf72: at the intersection of lysosome cell biology and neurodegenerative disease. Traffic vol. 2017;18:267&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389918</ArticleId><ArticleId IdType="pubmed">28266105</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. 2018;24:313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, et al. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat. Neurosci. 2020;23:615&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="pubmed">32284607</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne, C. et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA110, E4530&#x2013;E4539 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 2013;126:845&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. HnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol. 2013;125:413&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">23381195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 2013;5:208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl Acad. Sci. USA. 2013;110:E4968&#x2013;E4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Belzil VV, Zhang YJ, Petrucelli L. Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathologica. 2014;127:359&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4002260</ArticleId><ArticleId IdType="pubmed">24394885</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x10c;esnik, A. B. et al. Nuclear RNA foci from C9ORF72 expansion mutation form paraspeckle-like bodies. J. Cell Sci. 132, jcs224303 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30745340</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JD, Ranum LPW. Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders. Curr. Opin. Genet. Dev. 2014;26:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237677</ArticleId><ArticleId IdType="pubmed">24852074</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry, M. &amp; Usdin, K. Human Nucleotide Expansion Disorders (Springer, 2006).</Citation></Reference><Reference><Citation>Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 2007;30:575&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl Acad. Sci. USA. 2011;108:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 2013;126:829&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, et al. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 2014;128:485&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Eshov A, Zhou J, Isiktas AU, Guo JU. C9orf72 arginine-rich dipeptide repeats inhibit UPF1-mediated RNA decay via translational repression. Nat. Commun. 2020;11:3354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7335171</ArticleId><ArticleId IdType="pubmed">32620797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska, S. et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science27, 1192&#x2013;1194 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>West RJH, et al. Co-expression of C9orf72 related dipeptide-repeats over 1000 repeat units reveals age- and combination-specific phenotypic profiles in Drosophila. Acta Neuropathol. Commun. 2020;8:158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7487709</ArticleId><ArticleId IdType="pubmed">32894207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y.-J. et al. Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science363, eaav2606 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci. 2016;19:668&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, et al. Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat. Med. 2018;24:1136&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6520050</ArticleId><ArticleId IdType="pubmed">29942091</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, et al. FTD/ALS-associated poly(GR) protein impairs the Notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. Acta Neuropathol. 2015;130:525&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575383</ArticleId><ArticleId IdType="pubmed">26031661</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SY, et al. C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nat. Neurosci. 2019;22:851&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="pubmed">31086314</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinek M, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6286148</ArticleId><ArticleId IdType="pubmed">22745249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature. 2014;507:62&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106473</ArticleId><ArticleId IdType="pubmed">24476820</ArticleId></ArticleIdList></Reference><Reference><Citation>Single ascending dose study in participants with LCA10&#x2014;full text view&#x2014;ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03872479.</Citation></Reference><Reference><Citation>A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease&#x2014;full text view&#x2014;ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03745287.</Citation></Reference><Reference><Citation>Intellia Therapeutics. Phase 1 Two-Part (Open-label, Single Ascending Dose (Part 1) and Open-label, Single Dose Expansion (Part 2)) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN). https://clinicaltrials.gov/ct2/show/NCT04601051 (2020).</Citation></Reference><Reference><Citation>Giannoukos G, et al. UDiTaSTM, a genome editing detection method for indels and genome rearrangements. BMC Genomics. 2018;19:212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5861650</ArticleId><ArticleId IdType="pubmed">29562890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X-H, Tee LY, Wang X-G, Huang Q-S, Yang S-H. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol. Ther. Nucleic Acids. 2015;4:e264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4877446</ArticleId><ArticleId IdType="pubmed">26575098</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron. 2015;88:902&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>Leko, M. B. et al. Molecular mechanisms of neurodegeneration related to C9orf72 hexanucleotide repeat expansion. Behav. Neurol. 2019, 1&#x2013;18 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6350563</ArticleId><ArticleId IdType="pubmed">30774737</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, et al. C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron. 2016;90:521&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron. 2014;83:1043&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson JL, et al. Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. Mol. Neurodegener. 2020;15:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6993399</ArticleId><ArticleId IdType="pubmed">32000838</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol. 2015;129:715&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">25716178</ArticleId></ArticleIdList></Reference><Reference><Citation>Esanov R, et al. A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD. Mol. Neurodegener. 2017;12:46&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5468954</ArticleId><ArticleId IdType="pubmed">28606110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y-B, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5:1178&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J, et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain J. Neurol. 2012;135:723&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">22300876</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, et al. Artificial microRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients. Mol. Ther. Nucleic Acids. 2019;14:593&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LR, Duan L, Bowen K, Kalab P, Rothstein JD. C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. eLife. 2020;9:e51685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7051184</ArticleId><ArticleId IdType="pubmed">32119645</ArticleId></ArticleIdList></Reference><Reference><Citation>Moens TG, et al. C9orf72 arginine-rich dipeptide proteins interact with ribosomal proteins in vivo to induce a toxic translational arrest that is rescued by eIF1A. Acta Neuropathol. 2019;137:487&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6514073</ArticleId><ArticleId IdType="pubmed">30604225</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade NS, et al. Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD. Mol. Neurodegener. 2020;15:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041170</ArticleId><ArticleId IdType="pubmed">32093728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbert MTW, et al. Long-read sequencing across the C9orf72 &#x2018;GGGGCC&#x2019; repeat expansion: implications for clinical use and genetic discovery efforts in human disease. Mol. Neurodegener. 2018;13:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6102925</ArticleId><ArticleId IdType="pubmed">30126445</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanlon KS, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat. Commun. 2019;10:4439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6769011</ArticleId><ArticleId IdType="pubmed">31570731</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisheit I, et al. Detection of deleterious on-target effects after HDR-mediated CRISPR editing. Cell Rep. 2020;31:107689.</Citation><ArticleIdList><ArticleId IdType="pubmed">32460021</ArticleId></ArticleIdList></Reference><Reference><Citation>Esanov R, et al. C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. Exp. Neurol. 2016;277:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4761318</ArticleId><ArticleId IdType="pubmed">26746986</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X, et al. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell. 2016;165:1238&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900885</ArticleId><ArticleId IdType="pubmed">27118425</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj, B. T. et al. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity. Nat. Commun. 9, 1&#x2013;14 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ababneh NA, et al. Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair. Hum. Mol. Genet. 2020;29:2200&#x2013;2217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7399532</ArticleId><ArticleId IdType="pubmed">32504093</ArticleId></ArticleIdList></Reference><Reference><Citation>Piao X, et al. Dual-gRNA approach with limited off-target effect corrects C9ORF72 repeat expansion in vivo. Sci. Rep. 2022;12:5672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983752</ArticleId><ArticleId IdType="pubmed">35383205</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 2012;11:54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, et al. Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathol. 2015;130:863&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655160</ArticleId><ArticleId IdType="pubmed">26437865</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite AJ, et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol. Aging. 2014;35:1779.e5&#x2013;1779.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet. 2014;23:3579&#x2013;3595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, et al. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol. Commun. 2016;4:51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4870812</ArticleId><ArticleId IdType="pubmed">27193190</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production and glomerulonephropathy in mice. Sci. Rep. 2016;6:23204&#x2013;23204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharjan N, K&#xfc;nzli C, Buthey K, Saxena S. C9ORF72 regulates stress granule formation and its deficiency impairs stress granule assembly, hypersensitizing cells to stress. Mol. Neurobiol. 2017;54:3062&#x2013;3077.</Citation><ArticleIdList><ArticleId IdType="pubmed">27037575</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci. Transl. Med. 2016;8:347ra93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, et al. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron. 2015;88:892&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672384</ArticleId><ArticleId IdType="pubmed">26637796</ArticleId></ArticleIdList></Reference><Reference><Citation>029099 - FVB/NJ-Tg(C9orf72)500Lpwr/J. https://www.jax.org/strain/029099 (2022).</Citation></Reference><Reference><Citation>Shao, Q. et al. C9orf72 deficiency promotes motor deficits of a C9ALS/FTD mouse model in a dose-dependent manner. Acta Neuropathol. Commun. 7, 1&#x2013;3 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6398253</ArticleId><ArticleId IdType="pubmed">30832726</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, et al. Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy. Mol. Ther. Nucleic Acids. 2019;16:26&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90:535&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, et al. Antibody therapy targeting RAN proteins rescues C9 ALS/FTD phenotypes in C9orf72 mouse model. Neuron. 2020;105:645&#x2013;662.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391607</ArticleId><ArticleId IdType="pubmed">31831332</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuris JA, et al. Efficient delivery of genome-editing proteins in vitro and in vivo. Nat. Biotechnol. 2015;33:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4289409</ArticleId><ArticleId IdType="pubmed">25357182</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CE, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat. Med. 2019;25:427&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6455975</ArticleId><ArticleId IdType="pubmed">30778238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibraheim R, et al. Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. Nat. Commun. 2021;12:6267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8560862</ArticleId><ArticleId IdType="pubmed">34725353</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong G, et al. A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo. Nat. Biotechnol. 2020;38:169&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008088</ArticleId><ArticleId IdType="pubmed">31873216</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillmore JD, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 2021;385:493&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">34215024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pausch P, et al. CRISPR-Cas&#x3a6; from huge phages is a hypercompact genome editor. Science. 2020;369:333&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8207990</ArticleId><ArticleId IdType="pubmed">32675376</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu LJ, Holmes BR, Aronin N, Brodsky MH. CRISPRseek: a bioconductor package to identify target-specific guide RNAs for CRISPR-Cas9 genome-editing systems. PLoS ONE. 2014;9:e108424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172692</ArticleId><ArticleId IdType="pubmed">25247697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu PD, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 2013;31:827&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969858</ArticleId><ArticleId IdType="pubmed">23873081</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795411</ArticleId><ArticleId IdType="pubmed">23287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson KA, Chateau ML, Porteus MH. Design and development of artificial zinc finger transcription factors and zinc finger nucleases to the hTERT locus. Mol. Ther. Nucleic Acids. 2013;2:e87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3650244</ArticleId><ArticleId IdType="pubmed">23612114</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement K, et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 2019;37:224&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6533916</ArticleId><ArticleId IdType="pubmed">30809026</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeier Z, et al. Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Exp. Neurol. 2015;271:241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586400</ArticleId><ArticleId IdType="pubmed">26099177</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards, J. A. &amp; Edwards, R. A. Fastq-pair: efficient synchronization of paired-end fastq files. Preprint at https://www.biorxiv.org/content/10.1101/552885v1 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/552885v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Karolchik D, et al. The UCSC table browser data retrieval tool. Nucleic Acids Res. 2004;32:D493&#x2013;D496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308837</ArticleId><ArticleId IdType="pubmed">14681465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>